Bioequivalence of Telmione Plus and Micardis Plus in Healthy Volunteers

Phase 1, randomised, open-label trial of hydrochlorothiazide + telmisartan in hypertension (HTN) (2 arms), sponsored by HK inno.N Corporation. Primary endpoints: Maximum Plasma Concentration (Cmax) of Telmisartan up to 72 hours, Area Under the Curve to the Last Quantifiable Concentration (AUClast) of Telmisartan up to 72 hours and 2 more. Started Jul 2021; status: completed.